It is identified that folate is low in the tumor microenvironment by performing metabolomics on melanoma tumors and adjacent normal tissue from warm autopsy patient specimens, and that it is possible to increase tumor growth in Folr2-/- mice by increasing serum folate to supraphysiologic concentrations with a high fola...
Matthew P. Zimmerman, Vasyl Zhabotynsky, Hai-Yang Wang et al.· bioRxiv· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is dependent on mutant KRAS and elevated autophagy for growth. Previously, we and others demonstrated that pharmacological inhibition of the KRAS ERK-MAPK pathway caused increased autophagic flux. Targeting this increased autophagic flux with inhibitors that block autophagic pr...
Seamus E. Degan, Mallory K. Roach, Jonathan M. DeLiberty et al.· Cancer Research· 0 citations
Mutational activation of the KRAS oncogene occurs in over 90% of pancreatic ductal adenocarcinoma (PDAC) patients, and plays a crucial role in tumor initiation, progression, and tumor maintenance. Historically considered undruggable, there has recently been a surge in efforts to develop and improve drugs that target...
Sarah E. Ackermann, Seamus E. Degan, Wen-Hsuan Chang et al.· Cancer Research· 0 citations
Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.
Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.